Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044811 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
NCT00044811 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 1,000 participants.
The verdict
NCT00044811, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma
Interventions
- DRUG Fexofenadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2002-03 |
| Est. Completion | 2003-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044811
The ClinicalTrials.gov registry entry for NCT00044811 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fexofenadine is the first listed.
NCT00044811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044811 about?
NCT00044811 is a clinical study titled "Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma". The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma
What is the current status of trial NCT00044811?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2002-03. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00044811?
The interventions under investigation include: Fexofenadine (DRUG).
Who is sponsoring clinical trial NCT00044811?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.